A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
ReACT
A Phase II Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
1 other identifier
interventional
127
1 country
45
Brief Summary
The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Dec 2011
Typical duration for phase_2
45 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
December 1, 2011
CompletedFirst Submitted
Initial submission to the registry
December 21, 2011
CompletedFirst Posted
Study publicly available on registry
December 23, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
May 17, 2016
CompletedFebruary 17, 2020
April 1, 2017
3.3 years
December 21, 2011
February 12, 2020
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Groups 1 and 2: Progression-free survival rate
Evaluate the antitumor activity of rindopepimut in adult patients with relapsed glioblastoma, as measured by the progression-free survival rate at 6 months post-Day 1 (PFS 6).
6 months post-Day 1
Group 2C: Objective Response Rate
Evaluate the anti-tumor activity of rindopepimut in adult patients with relapsed glioblastoma, as measured by the objective response rate (ORR) for patients with measurable disease at study entry.
Every 8 weeks from Day 1 through progression or initiation of other anti-cancer therapy
Secondary Outcomes (3)
Safety and Tolerability
Until 28 days or initiation of other anti-cancer treatment, whichever is first
Anti-tumor activity
During treatment and every 8 weeks through follow up
EGFRvIII-specific immune response
Several times during the first month of treatment and then approximately every 8 weeks until treatment is stopped.
Study Arms (3)
Group 1a: Bevacizumab NaĂ¯ve with Bevacizumab + rindopepimut.
EXPERIMENTALAbout half of the patients who have never received treatment with bevacizumab will receive rindopepimut/GM-CSF in a blinded fashion in combination with bevacizumab.
Group 1b: Bevacizumab NaĂ¯ve with Bevacizumab + KLH control
EXPERIMENTALAbout half of the patients who have never received treatment with bevacizumab will receive KLH in a blinded fashion in combination with bevacizumab.
Group 2 and 2C: Refractory to Bevacizumab
EXPERIMENTALPatients with progressive disease while currently on or within two months after discontinuing bevacizumab will be administered rindopepimut/GM-CSF while continuing (or restarting if they had stopped bevacizumab).
Interventions
A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
Eligibility Criteria
You may qualify if:
- Among other criteria, patients must meet the following conditions to be eligible for the study:
- Age ≥18 years of age.
- Histologic diagnosis of glioblastoma (WHO Grade IV).
- Documented EGFRvlll positive tumor status (central lab confirmation).
- First or second relapse of de novo glioblastoma or first diagnosis or first relapse of secondary glioblastoma.
- Previous treatment must include surgery, conventional radiation therapy and temozolomide (TMZ).
- Screening MRI must be obtained at least 4 weeks after any salvage surgery, and at least 12 weeks after radiation therapy.
- KPS of ≥ 70%.
- If applicable, systemic corticosteroid therapy must be at a dose of ≤ 4 mg of dexamethasone or equivalent per day during the week prior to Day 1.
- Evaluable disease in Groups 1 and 2; measurable disease in Group 2C
- Life expectancy \> 12 weeks.
- Patients in Group 2 and 2C must have had disease progression while receiving bevacizumab or within 2 months of treatment with bevacizumab.
You may not qualify if:
- Among other criteria, patients who meet the following conditions are NOT eligible for the study:
- Subjects unable to undergo an MRI with contrast.
- History, presence, or suspicion of metastatic disease
- Prior receipt of vaccination against EGFRvIII.
- Any known contraindications to receipt of study drugs, including known allergy or hypersensitivity to keyhole limpet hemocyanin (KLH), GM-CSF (sargramostim; LEUKINE®), polysorbate 80 or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.
- Use of non-protein based investigational therapy within 14 days prior to Day 1 or use of antibody-based investigational therapy within 28 days prior to Day 1.
- Clinically significant increased intracranial pressure (e.g., impending herniation), uncontrolled seizures, or requirement for immediate palliative treatment
- Evidence of recent hemorrhage on screening MRI of the brain
- Evidence of current drug or alcohol abuse.
- Patients in Group 1 must not have received prior treatment with bevacizumab.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (45)
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
St. Joseph's Hospital and Medical Center / Barrow Neurological Institute
Phoenix, Arizona, 85013, United States
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, 90027, United States
University of Southern California (USC) Norris Comprehensive Cancer Center
Los Angeles, California, 90089, United States
UC Irvine Chao Family Comprehensive Cancer Center
Orange, California, 92868, United States
University of California San Francisco
San Francisco, California, 94143, United States
Stanford Cancer Institute, Stanford University
Stanford, California, 94305, United States
University of Colorado, Denver
Aurora, Colorado, 80045, United States
Memorial Cancer Institute
Hollywood, Florida, 33021, United States
Orlando Health, Inc.
Orlando, Florida, 32806, United States
Tampa General Hospital
Tampa, Florida, 33606, United States
Piedmont Atlanta Hospital
Atlanta, Georgia, 30309, United States
Atlanta Cancer Care
Atlanta, Georgia, 30342, United States
Rush University Medical Center
Chicago, Illinois, 60612, United States
University of Chicago
Chicago, Illinois, 60637-1470, United States
NorthShore University Health System
Evanston, Illinois, 60201, United States
The Johns Hopkins Hospital
Baltimore, Maryland, 21287, United States
Dana-Farber Cancer Institute and Mass General Hospital
Boston, Massachusetts, 02115, United States
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109, United States
Sparrow Cancer Center
Lansing, Michigan, 48912, United States
John Nasseff Neuroscience Institute, Abbott Northwestern Hospital, 800 e. 28th Str. MR
Minneapolis, Minnesota, 55407, United States
Washington University School of Medicine
St Louis, Missouri, 63110, United States
New Jersey Neuroscience Institute JFK Medical Center
Edison, New Jersey, 08818, United States
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
Dent Neurologic Institute, 3980 Sheridan Dr, 3rd Flr Clinical Rsch
Amherst, New York, 14226, United States
The Long Island Brain Tumor Center at Neurology Surgery, P.C.
Commack, New York, 11725, United States
University of Rochester Medical Center
Rochester, New York, 14642, United States
Stony Brook University Hospital
Stony Brook, New York, 11794-8121, United States
The Preston Robert Tisch Brain Tumor Center; Duke University Medical Center
Durham, North Carolina, 27710, United States
Wake Forest Baptist Health
Winston-Salem, North Carolina, 27157, United States
University of Cincinnati Cancer Institute
Cincinnati, Ohio, 45267, United States
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
Cleveland, Ohio, 44106, United States
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
Cleveland, Ohio, 44195, United States
Legacy Research Institute
Portland, Oregon, 97232, United States
Lehigh Valley Hospital-John and Dorothy Morgan Cancer Center
Allentown, Pennsylvania, 18103, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, 15232, United States
Rhode Island Hospital
Providence, Rhode Island, 02903, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, 37232, United States
Texas Oncology Midtown
Austin, Texas, 78705, United States
Baylor Research Institute
Dallas, Texas, 75246, United States
UT Health Science Center, Houston Memorial Hermann Hospital, 6400 Fannin Street, #2800
Houston, Texas, 77030, United States
Utah Cancer Specialists
Salt Lake City, Utah, 84116, United States
Swedish Neuroscience Research
Seattle, Washington, 98122, United States
University of Washington Medical Center
Seattle, Washington, 98195, United States
Related Publications (2)
Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, Ashby LS, Duic JP, Mrugala MM, Cruickshank S, Vitale L, He Y, Green JA, Yellin MJ, Turner CD, Keler T, Davis TA, Sampson JH; ReACT trial investigators. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial. Clin Cancer Res. 2020 Apr 1;26(7):1586-1594. doi: 10.1158/1078-0432.CCR-18-1140. Epub 2020 Feb 7.
PMID: 32034072RESULTGatson NT, Weathers SP, de Groot JF. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma. CNS Oncol. 2016;5(1):11-26. doi: 10.2217/cns.15.38. Epub 2015 Dec 15.
PMID: 26670466DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
- Expanded Access
- Yes
Study Record Dates
First Submitted
December 21, 2011
First Posted
December 23, 2011
Study Start
December 1, 2011
Primary Completion
April 1, 2015
Study Completion
May 17, 2016
Last Updated
February 17, 2020
Record last verified: 2017-04